2024 |
BRCA-associated hereditary male cancers: can gender affect the prevalence and spectrum of germline pathogenic variants? |
Articolo in rivista |
Go to |
2024 |
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints |
Review essay (rassegna critica) |
Go to |
2023 |
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window? |
Articolo in rivista |
Go to |
2022 |
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning |
Articolo in rivista |
Go to |
2021 |
Not all KIT 557/558 codons mutations have the same prognostic influence on recurrence-free survival: breaking the exon 11 mutations in gastrointestinal stromal tumors (GISTs) |
Articolo in rivista |
Go to |
2021 |
Impact of deleterious variants in other genes beyond BRCA1/2 detected in breast/ovarian and pancreatic cancer patients by NGS-based multi-gene panel testing: looking over the hedge |
Articolo in rivista |
Go to |
2021 |
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome |
Articolo in rivista |
Go to |
2020 |
Hereditary breast and ovarian cancer in families from southern Italy (Sicily)—Prevalence and geographic distribution of pathogenic variants in BRCA1/2 genes |
Articolo in rivista |
Go to |
2020 |
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype–phenotype correlation in a cohort of 531 patients |
Articolo in rivista |
Go to |